<DOC>
	<DOCNO>NCT01189474</DOCNO>
	<brief_summary>Multicentric study , open label , uncontrolled phase IV 140 patient meibomian gland dysfunction . Its objective Collect information patient ophthalmologists specialized ocular surface eyelid anticipate Blephasteam ® optimize . This study involve 2 visit , visit Inclusion , J0 , end study visit , D21 . Between two visit patient treat Blephasteam ® 21 day ( two us per day ) complete questionnaire every two day first week week next two week .</brief_summary>
	<brief_title>Evaluation Satisfaction Regarding Patient 's Management Ocular Surface Diseases</brief_title>
	<detailed_description />
	<mesh_term>Eyelid Diseases</mesh_term>
	<criteria>Signed date informed consent . Male female 4 year old . Known treated symptomatic Meibomian Gland Diseases , and/or Dry Eye relate MGDs stable since least month . Without active pathology require change ocular treatment within last month inclusion . Best correct far visual acuity ( VA ) &gt; 1/10</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Meibomian Gland Dysfunction</keyword>
</DOC>